<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139597">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01963182</url>
  </required_header>
  <id_info>
    <org_study_id>2013-001275-21</org_study_id>
    <nct_id>NCT01963182</nct_id>
  </id_info>
  <brief_title>Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer</brief_title>
  <acronym>IriGen</acronym>
  <official_title>Phase II Study: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, non randomized multicenter phase II study, will determine the feasibility
      of individualized dose of irinotecan with the UGT1A1 polymorphism, in patients with
      metastatic colorectal cancer treated with FOLFIRI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>severe toxicity (according to NCI-CTC cotation) and response with adapted dose of irinotecan</measure>
    <time_frame>during the treatment (an expected average of 7 months)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study of the blood concentration (pharmacokinetic) of irinotecan, the SN38 and SN38-G, and bevacizumab</measure>
    <time_frame>during the first 24 hours of the first cure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of treatment efficacy (progression-free survival, duration of response)</measure>
    <time_frame>to progression (1 year)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>First Line Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>irinotecan dose based on genetic polymorphism of UGT1A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>irinotecan dose based on genetic polymorphism of UGT1A1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Colorectal cancer histologically or cytologically proven

          -  Indication of treatment according to the FOLFIRI + / - bevacizumab

          -  Age&gt; 18 years

          -  Presence of at least one measurable target by RECIST

          -  Life expectancy&gt; 3 months

          -  Satisfactory biological functions (renal, hepatic and hematologic)

          -  Affiliation to a social security scheme (or be the beneficiary of such a plan) under
             the terms of the Act of August 9, 2004

          -  Patient has signed, after informing the informed consent form

        Exclusion Criteria:

          -  Patients of childbearing age and not using effective contraception during treatment
             and for at least three months after the end of treatment with irinotecan and at least
             six months after the end of treatment with bevacizumab and patient pregnant or
             nursing

          -  Patient with another pathology deemed incompatible with the entry in the protocol

          -  Prior treatment in metastatic

          -  Patients taking antiepileptic

          -  Allergic reaction or intolerance to irinotecan

          -  Heart failure , kidney , bone marrow , liver or respiratory

          -  Higher bilirubin 1.5 times the upper limit of normal

          -  Significant psychiatric or neurological abnormality

          -  Infectious syndrome requiring treatment with antibiotics or antiviral long-term

          -  Patients with chronic inflammatory bowel disease and / or bowel obstruction

          -  Contraindication Association St. John's wort and yellow fever vaccine

          -  Against Heart indication 5-FU

          -  Concurrent treatment with a drug test , participation in a clinical trial within &lt;30
             days

          -  Patient refused to sign the consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier DURANDO, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pauline HERVIOU</last_name>
    <phone>33463663358</phone>
    <email>pauline.herviou@cjp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique de la Châtaigneraie</name>
      <address>
        <city>Beaumont</city>
        <zip>63110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier DURANDO, MD, PhD</last_name>
      <phone>33473278103</phone>
      <email>Xavier.DURANDO@cjp.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier DURANDO, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline PETORIN, MD</last_name>
      <phone>33473750508</phone>
      <email>cpetorin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline PETORIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
